Thrombolytic therapy has been available for the last 5 decades, but the modern era of thrombolysis began in the early 1990s, with the execution of 3 multicenter trials designed to compare this potentially less invasive therapy to the then standard of care for acute limb ischemia, open surgical revascularization. Even with the development of several bioengineered lytic agents, the major risk of thrombolytic therapy continues to be bleeding complications. Nevertheless, data exist to suggest that thrombolysis should be considered as an adjunct to open surgery, percutaneous interventions, or, occasionally, as sole therapy for acute vascular occlusion. This review summarizes the developmental milestones in the history of thrombolysis and reviews data supporting its use in acute arterial occlusions.
FaggioliGLPeerRMPedriniL. Failure of thrombolytic therapy to improve long-term vascular patency. J Vasc Surg.1994;19:289–296.
2.
KornPKhilnaniNMFellersJC. Thrombolysis for native arterial occlusions of the lower extremities: clinical outcome and cost. J Vasc Surg.2001;33:1148–1157.
3.
SullivanKLGardinerGAKandarpaK. Efficacy of thrombolysis in infrainguinal bypass grafts. Circulation. 1991;83(2 Suppl):I99–105.
4.
TillettWSGarnerRL. The fibrinolytic activity of hemolytic streptococci. J Exp Med.1933;58:485.
5.
TillettWSSherryS. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest. 1949;28:173.
6.
TillettWSJohnsonAJMcCartyWR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest. 1955;34:169–185.
7.
ClifftonEEGrunnetM. Investigations of intravenous plasmin (fibrinolysin) in humans. Circulation. 1956;14:919.
8.
ClifftonEE. The use of plasmin in humans. Ann N Y Acad Sci.1957;68:209–229.
9.
DotterCTRöschJSeamanAJ. Selective clot lysis with low-dose streptokinase. Radiology. 1974;111:31–37.
10.
van BredaARobisonJCFeldmanL. Local thrombolysis in the treatment of arterial graft occlusions. J Vasc Surg.1984;1:103–112.
11.
GraorRARisiusBDennyKM. Local thrombolysis in the treatment of thrombosed arteries, bypass grafts, and arteriovenous fistulas. J Vasc Surg.1985;2:406–414.
12.
MacfarlaneRGPillingJJ. Fibrinolytic activity of normal urine. Nature. 1947;159:779.
13.
SobelGWMohlerSRJonesNW. Urokinase: an activator of plasma fibrinolysin extracted from urine. Am J Physiol. 1952;171:768–769.
14.
CredoRBBurkeSEBarkerWM. Recombinant urokinase (r-UK): biochemistry, pharmacology, and clinical experience. In: SasaharaAALoscalzoJ, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, Inc.; 1997:513–537.
15.
HusainSSLipinskiBGurewichV. Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chair, high-fibrin affinity urokinase). US patent 4,381,346. 1979.
16.
McNamaraTOFischerJR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR Am J Roentgenol. 1985;144:769–775.
17.
HoylaertsMRijkenDCLijnenHR. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem.1982;257:2912–2919.
18.
The GUSTO Investigators. An international randomized trial comparing four thrombolytic therapies for acute myocardial infarction. N Engl J Med.1993;329:673–682.
19.
KeytBAPaoniNFRefinoCJ. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994;91:3670–3674.
20.
CannonCPMcCabeCHGibsonCM. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351–356.
21.
MartinU. Clinical and preclinical profile of the novel recombinant plasminogen activator reteplase. In: SasaharaAALoscalzoJ, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, Inc.; 1997:495–511.
22.
MeierhenrichRCarlssonJSeifriedE. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Int J Cardiol. 1998;65:57–63.
23.
OurielKKatzenBMewissenM. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol. 2000;11:849–854.
24.
McNamaraTODongPChenJ. Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions. Tech Vasc Interv Radiol. 2001;4:92–98.
25.
MewissenMW. Catheter-directed thrombolysis for lower extremity deep vein thrombosis. Tech Vasc Interv Radiol. 2001;4:111–114.
26.
OurielKShortellCKDeWeeseJA. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral ischemia. J Vasc Surg.1994;19:1021–1030.
27.
Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg.1994;220:251–268.
28.
WeaverFAComerotaAJYoungbloodM. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. J Vasc Surg.1996;24:513–523.
29.
ComerotaAJWeaverFAHoskingJD. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg.1996;172:105–112.
30.
OurielKVeithFJSasaharaAA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg.1996;23:64–75.
31.
OurielKVeithFJSasaharaAA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med.1998;338:1105–1111.
